The additional risk factors for urinary tract infections associated with SGLT2 inhibitors include duration of diabetes, age over 65 years, proteinuria, eGFR ≤ 60 mL/min/1.72 m2, urinary tract obstruction and the presence of a lower urinary tract infection such as cystitis or bacteriuria at the baseline when initiating this class of drugs [44,45,46]. This evidence concerns the gene SLC5A2 and diabetes mellitus.